Standards of measurements in myasthenia gravis

被引：27

作者：

Barohn, RJ ^{[1
]}

机构：

[1] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA

来源：

MYASTHENIA GRAVIS AND RELATED DISORDERS: BIOCHEMICAL BASIS FOR DISEASE OF THE NEUROMUSCULAR JUNCTION | 2003年 / 998卷

关键词：

myasthenia gravis (MG); recommendations; measurement;

D O I：

10.1196/annals.1254.056

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In 1997, the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America formed a Task Force to develop classification and outcome measures for myasthenia gravis (MG). The goal of the Task Force was to achieve uniformity in recording and reporting clinical trials and outcomes research. The Task Force met frequently over a three-year period, obtained input from national and international experts, and produced a consensus document on recommendations for MG clinical research standards. In this article, the essential elements of the Task Force's recommendations will be summarized. In addition, several other MG measurement tools that are in various stages of development are mentioned.

引用

页码：432 / 439

页数：8

共 21 条

[1]

BAROHN R, 1994, J CHILD NEUROL, V9, P205

[2] Reliability testing of the quantitative myasthenia gravis score [J].

Barohn, RJ ;

McIntire, D ;

Herbelin, L ;

Wolfe, GI ;

Nations, S ;

Bryan, WW .

MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 :769-772

[3]

BAROHN RJ, 1996, ADM QUANTITATIVE MYA

[4] LONG-TERM CORRELATION OF CLINICAL COURSE AND ACETYLCHOLINE-RECEPTOR ANTIBODY IN PATIENTS WITH MYASTHENIA-GRAVIS [J].

BESINGER, UA ;

TOYKA, KV ;

HEININGER, K ;

FATEHMOGHADAM, A ;

SCHUMM, F ;

SANDEL, P ;

BIRNBERGER, KL .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1981, 377 (DEC) :812-815

[5] MYASTHENIA-GRAVIS - LONG-TERM CORRELATION OF BINDING AND BUNGAROTOXIN BLOCKING ANTIBODIES AGAINST ACETYLCHOLINE-RECEPTORS WITH CHANGES IN DISEASE SEVERITY [J].

BESINGER, UA ;

TOYKA, KV ;

HOMBERG, M ;

HEININGER, K ;

HOHLFELD, R ;

FATEHMOGHADAM, A .

NEUROLOGY, 1983, 33 (10) :1316-1321

[6] Mycophenolate mofetil for myasthenia gravis: An open-label pilot study [J].

Ciafaloni, E ;

Massey, JM ;

Tucker-Lipscomb, B ;

Sanders, DB .

NEUROLOGY, 2001, 56 (01) :97-99

[7] FUNCTIONAL ACTIVITIES OF AUTOANTIBODIES TO ACETYLCHOLINE-RECEPTORS AND THE CLINICAL SEVERITY OF MYASTHENIA-GRAVIS [J].

DRACHMAN, DB ;

ADAMS, RN ;

JOSIFEK, LF ;

SELF, SG .

NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (13) :769-775

[8]

Herbelin LL, 2001, NEUROLOGY, V56, pA63

[9] Myasthenia gravis - Recommendations for clinical research standards [J].

Jaretzki, A ;

Barohn, RJ ;

Ernstoff, RM ;

Kaminski, HJ ;

Keesey, JC ;

Penn, AS ;

Sanders, DB .

NEUROLOGY, 2000, 55 (01) :16-23

[10]

JARETZKI A, 1988, J THORAC CARDIOV SUR, V95, P747

← 1 2 3 →